Fangqing Wang1, Yanying Li1, Hong Jiang1, Chenglei Li2, Zhaohuan Li2, Cuiping Qi3, Zhipeng Li1, Zhiqin Gao1, Bo Zhang2, Jingliang Wu1. 1. School of Bioscience and Technology, Weifang Medical University, Weifang, 261053, People's Republic of China. 2. School of Pharmacy, Weifang Medical University, Weifang, 261053, People's Republic of China. 3. School of Nursing, Weifang Medical University, Weifang, 261053, People's Republic of China.
Abstract
BACKGROUND: Tumor angiogenesis has been proven to potentiate tumor growth and metastasis; therefore, the strategies targeting tumor-related angiogenesis have great potentials in antitumor therapy. METHODS: Here, the GA&Gal dual-ligand-modified liposomes co-loaded with curcumin and combretastatin A-4 phosphate (CUCA/GA&Gal-Lip) were prepared and characterized. A novel "BEL-7402+HUVEC" co-cultured cell model was established to mimic tumor microenvironment. The cytotoxicity and migration assays were performed against the novel co-cultured model. Angiogenesis ability was evaluated by tube formation test, and in vivo metastatic ability was evaluated by lung metastasis test. RESULTS: The result demonstrated that dual-ligand-modified liposomes showed greater inhibition of tumor angiogenesis and metastasis in comparison with other combined groups. Significantly, the mechanism analysis revealed that curcumin and combretastatin A-4 phosphate could inhibit tumor angiogenesis and metastasis via down-regulation of VEGF and VEGFR2 expression, respectively, and that GA&Gal-Lip could improve antitumor effect by GA/Gal-mediated active-targeting delivery. CONCLUSION: CUCA/GA&Gal-Lip hold great potentials in hepatoma-targeting delivery of antitumor drugs and can achieve anti-angiogenic and anti-metastatic effects by simultaneously blocking VEGF/VEGFR2 signal pathway, therefore exhibiting superior anti-hepatoma efficacy.
BACKGROUND: Tumor angiogenesis has been proven to potentiate tumor growth and metastasis; therefore, the strategies targeting tumor-related angiogenesis have great potentials in antitumor therapy. METHODS: Here, the GA&Gal dual-ligand-modified liposomes co-loaded with curcumin and combretastatin A-4 phosphate (CUCA/GA&Gal-Lip) were prepared and characterized. A novel "BEL-7402+HUVEC" co-cultured cell model was established to mimic tumor microenvironment. The cytotoxicity and migration assays were performed against the novel co-cultured model. Angiogenesis ability was evaluated by tube formation test, and in vivo metastatic ability was evaluated by lung metastasis test. RESULTS: The result demonstrated that dual-ligand-modified liposomes showed greater inhibition of tumor angiogenesis and metastasis in comparison with other combined groups. Significantly, the mechanism analysis revealed that curcumin and combretastatin A-4 phosphate could inhibit tumor angiogenesis and metastasis via down-regulation of VEGF and VEGFR2 expression, respectively, and that GA&Gal-Lip could improve antitumor effect by GA/Gal-mediated active-targeting delivery. CONCLUSION: CUCA/GA&Gal-Lip hold great potentials in hepatoma-targeting delivery of antitumor drugs and can achieve anti-angiogenic and anti-metastatic effects by simultaneously blocking VEGF/VEGFR2 signal pathway, therefore exhibiting superior anti-hepatoma efficacy.
Authors: B Shan; C Schaaf; A Schmidt; K Lucia; M Buchfelder; M Losa; D Kuhlen; J Kreutzer; M J Perone; E Arzt; G K Stalla; U Renner Journal: J Endocrinol Date: 2012-06-27 Impact factor: 4.286
Authors: A R Hussain; M Al-Rasheed; P S Manogaran; K A Al-Hussein; L C Platanias; K Al Kuraya; S Uddin Journal: Apoptosis Date: 2006-02 Impact factor: 4.677
Authors: Han-A Park; Pawel Licznerski; Nelli Mnatsakanyan; Yulong Niu; Silvio Sacchetti; Jing Wu; Brian M Polster; Kambiz N Alavian; Elizabeth A Jonas Journal: Cell Death Differ Date: 2017-08-04 Impact factor: 15.828
Authors: Zhi-Peng Li; Gui-Xiang Tian; Hong Jiang; Rui-Yan Pan; Bo Lian; Min Wang; Zhi-Qin Gao; Bo Zhang; Jing-Liang Wu Journal: Int J Nanomedicine Date: 2019-12-02